Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

24.7K
Hepatitis C Virus (HCV) is a major human pathogen that causes liver disorders, including cirrhosis and cancer. An HCV infectious cell culture system is essential for understanding the molecular mechanism of HCV replication and developing new therapeutic approaches. Here we describe a protocol to investigate various stages of the HCV replication cycle.
24.7K
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

7.9K
This manuscript describes a detailed protocol for Hepatitis B virus (HBV) infection in novel engineered 293T cells (293T-NE-3NRs, expressing human NTCP, HNF4α, RXRα and PPARα) and traditional hepatic cells (HepG2-NE, expressing human...
7.9K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

13.9K
Here we describe a newly developed hepatitis B virus (HBV) reporter system to monitor the early stages of the HBV life cycle. This simplified in vitro system will aid in the screening of anti-HBV agents using a high-throughput...
13.9K
Targeting Liver Tumors with Oncolytic Viruses via the Hepatic Artery04:46

Targeting Liver Tumors with Oncolytic Viruses via the Hepatic Artery

596
The video demonstrates locoregional delivery of oncolytic viruses through hepatic arterial injection as a therapeutic approach for hepatocellular carcinoma. These viruses selectively replicate in tumor cells, inducing cell lysis and releasing tumor cell-associated antigens. This process triggers immunogenic cell death, inducing an anti-tumor...
596
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

10.3K
Described here is an effective method on how to produce high viral titer stocks of hepatitis E virus (HEV) to efficiently infect hepatoma cells. With the presented method, both non-enveloped, as well as enveloped viral particles can be harvested and used for inoculating various cell...
10.3K
Hepatic Progenitor Specification from Pluripotent Stem Cells using a Defined Differentiation System07:09

Hepatic Progenitor Specification from Pluripotent Stem Cells using a Defined Differentiation System

5.4K
The goal of this article is to provide a standardized approach to induce human hepatic progenitor differentiation from pluripotent stem cells. The development of this procedure with ready-to-use media formulations offer the user a facile system to generate human liver cells for biomedical research and...
5.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human RIG-I Antiviral Deficiency Caused by a Dominant-Negative Variant Locked in a Signaling-Inactive State.

medRxiv : the preprint server for health sciences·2026
Same author

Structural heterogeneity of apolipoprotein B-100.

The FEBS journal·2026
Same author

CD81 is a receptor for equine arteritis virus (family: <i>Arteriviridae</i>).

mBio·2025
Same author

Structure of apolipoprotein B100 bound to the low-density lipoprotein receptor.

Nature·2024
Same author

Influenza A virus transcription generates capped cRNAs that activate RIG-I.

bioRxiv : the preprint server for biology·2024
Same author

Structure-guided assembly of an influenza spike nanobicelle vaccine provides pan H1 intranasal protection.

bioRxiv : the preprint server for biology·2024

Related Experiment Video

Updated: Jan 19, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.7K

Hepatitis C Virus Structure: Defined by What It Is Not.

Altaira D Dearborn1,2, Joseph Marcotrigiano1

  • 1The Protein Expression Laboratory, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.

Cold Spring Harbor Perspectives in Medicine
|September 11, 2019
PubMed
Summary
This summary is machine-generated.

Hepatitis C virus (HCV) causes chronic liver disease globally. A new vaccine is urgently needed as current therapies are expensive and do not prevent reinfection, highlighting the need for structural insights into HCV components.

More Related Videos

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.9K

Related Experiment Videos

Last Updated: Jan 19, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.7K
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.9K

Area of Science:

  • Virology
  • Hepatology
  • Immunology

Background:

  • Hepatitis C virus (HCV) infects 70 million worldwide, causing chronic liver disease, cirrhosis, and cancer.
  • Rising HCV infections in the US are linked to increased intravenous drug use.
  • Existing curative therapies are costly and do not prevent reinfection, necessitating vaccine development.

Purpose of the Study:

  • To review structural advancements in understanding the Hepatitis C virus (HCV) virion.
  • To elucidate the structure and function of HCV core protein and envelope glycoproteins (E1, E2).
  • To examine the structural basis of HCV interaction with host receptors CD81 and SR-BI.

Main Methods:

  • Review of existing literature on HCV structure and host interactions.
  • Analysis of structural data for HCV virion, core protein, and envelope glycoproteins.
  • Examination of studies on host cell receptors (CD81, SR-BI) involved in HCV entry.

Main Results:

  • HCV virions are asymmetric and heterogeneous, resembling lipoparticles.
  • HCV core protein is unstructured.
  • HCV E2 glycoprotein mediates binding to CD81 and SR-BI receptors, while E1 function remains unclear.

Conclusions:

  • Structural understanding of HCV components is crucial for vaccine design.
  • Targeting E2-receptor interactions may offer therapeutic or preventative strategies.
  • Further research into E1's function is needed for a comprehensive understanding of HCV infection.